Skip to main content
Brett Theeler, MD, Neurology, Bethesda, MD

Brett James Theeler MD

Neurooncology


Chair, Department of Neurology Uniformed Services University School of Medicine

Join to View Full Profile
  • Walter Reed National Military Medical CenterBethesda, MD 20889

  • Phone+1 301-295-4771

  • Fax+1 301-295-4771

Dr. Theeler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2010 - 2012
  • Madigan Army Medical Center
    Madigan Army Medical CenterResidency, Neurology, 2005 - 2009
  • Uniformed Services University of the Health Sciences F. Edward Hebert School of Medicine
    Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2005

Certifications & Licensure

  • SD State Medical License
    SD State Medical License Active through 2027
  • IN State Medical License
    IN State Medical License 2007 - 2017
  • Neurology
    American Board of Psychiatry and Neurology Neurology
  • Neuro-Oncology
    United Council for Neurologic SubspecialtiesNeuro-Oncology

Publications & Presentations

PubMed

Journal Articles

  • Clinical Decision Making in the Era of Immunotherapy for High Grade-Glioma: Report of Four Cases  
    Martha Quezado, Brett J Theeler, Deric M Park, Edjah Nduom, Nancy Garren, Surabhi Ranjan, Kareem A Zaghloul, BioMed Central

Press Mentions

  • Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH
    Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIHNovember 18th, 2020
  • Alexandria Man to Stand up for 24 Hours Straight in Cancer Fundraising Act
    Alexandria Man to Stand up for 24 Hours Straight in Cancer Fundraising ActFebruary 9th, 2020
  • Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
    Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206September 20th, 2019
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: